Why perform randomized clinical trials for sentinel node surgery for breast cancer?

Area of Science:

• Oncology
• Surgical Oncology
• Clinical Trials

Background:

• The long-term outcomes and therapeutic efficacy of sentinel node surgery (SNS) alone, without proceeding to axillary dissection (AD), remain incompletely established.
• Current clinical practice often involves AD for node-positive breast cancer patients, despite potential morbidity.

Purpose of the Study:

• To establish the therapeutic equivalence of sentinel node surgery without axillary dissection compared to traditional axillary dissection.
• To evaluate the impact of both surgical approaches on survival, long-term regional control, and patient morbidity.

Main Methods:

• Two major clinical trials are underway comparing SNS without AD to standard AD.
• The National Surgical Adjuvant Breast and Bowel Project (NSABP) trial primarily focuses on node-negative breast cancer.
• The American College of Surgeons Clinical Oncology Group (ACOSOG) trial randomizes node-positive breast cancer patients.

Main Results:

• Primary endpoints for both trials include survival rates, long-term regional cancer control, and treatment-related morbidity.
• Data from these trials will provide a narrow confidence interval regarding the efficacy and safety of SNS alone.
• The studies aim to determine if SNS without AD offers comparable therapeutic benefits to AD with reduced complications.

Conclusions:

• The ongoing NSABP and ACOSOG trials are critical for defining the role of sentinel node surgery in breast cancer management.
• Results will clarify whether omitting axillary dissection in favor of sentinel node surgery provides equivalent oncological outcomes with decreased morbidity.
• Establishing the long-term effectiveness of sentinel node surgery alone is essential for optimizing breast cancer treatment guidelines.